# US 2013/0156778 A1 · Dendritic cell inhibitory proteins from ticks

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0156778 A1
- Document ID: US20130156778A1
- Status: Published application
- Kind: A1
- Application number: 13/636,469
- Filed: 2011-03-23
- Published: 2013-06-20
- Earliest claimed: 2010-03-23
- Assignees: Natural Environment Research Council
- Inventors: Jonathan M. Austyn; Guido Paesen; Stephen Preston; Patricia Nuttal
- Web page: https://patentgrep.com/patent/US20130156778A1

## CPC

- C07K 14/43527: {from ticks}
- A61K 38/1767: {from invertebrates}
- A61K 39/0003: {Invertebrate antigens}
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 40/19: Dendritic cells
- A61K 40/22: Immunosuppressive or immunotolerising
- A61K 40/24: Antigen-presenting cells [APC]
- A61K 40/416: {Antigens related to auto-immune diseases; Preparations to induce self-tolerance}
- A61K 40/418: {Antigens related to induction of tolerance to non-self}
- A61K 40/42: Cancer antigens
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 35/00: Antineoplastic agents
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/4702: {Regulators; Modulating activity}
- C07K 16/18: against material from animals or humans
- C12N 5/0639: {Dendritic cells, e.g. Langherhans cells in the epidermis}
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention provides a dendritic cell modulatory protein which modulates, and preferably inhibits, the differentiation and/or maturation of mammalian dendritic cells. The invention also provides proteins comprising conserved motifs found in such proteins as well as pharmaceutical compositions comprising the dendritic cell modulatory protein and homologues and active fragments thereof, antibodies thereto and methods of treatment which utilise such proteins, homologues, fragments and antibodies.

## Claims

### Claim 1

A dendritic cell (DC) modulatory protein, wherein said protein modulates mammalian DC differentiation and maturation and comprises:
i) the amino acid sequence of any one of a) SEQ ID NOs: 2, 25 or 28 (RaA); b) SEQ ID NOs: 4, 26 or 29 (RaB); or c) SEQ ID NOs: 6, 24 or 27 (Rs1);
ii) a homologue of a protein as defined in i) having at least 40% identity thereto; or
iii) an active fragment of a protein as defined in i) above or of a homologue as defined in ii) above.

### Claim 2 (depends on 1)

The DC modulatory protein of claim 1 wherein the DC modulatory protein comprises the amino acid sequence of any one of SEQ ID NOs 2, 4 or 6.

### Claim 3 (depends on 1, 2)

The DC modulatory protein of claim 1 or 2, wherein the protein has at least 47% identity to the amino acid sequence of SEQ ID NO: 2.

### Claim 4 (depends on 1, 2)

The DC modulatory protein of claim 1 or 2, wherein the protein has at least 53% identity to the amino acid sequence of SEQ ID NO: 4.

### Claim 5 (depends on 1, 2)

The DC modulatory protein of claim 1 or 2, wherein the protein has at least 81% identity to the amino acid sequence of SEQ ID NO: 6.

### Claim 6 (depends on 1, 2)

The DC modulatory protein of claim 1 or 2 wherein the protein does not have the amino acid sequence of any one of SEQ ID NOs: 8, 10, 12, 14 or 16.

### Claim 7

The DC modulatory protein of any one of the preceding claims, wherein said protein is glycosylated at one or more positions.

### Claim 8 (depends on 7)

The DC modulatory protein of claim 7, wherein said protein comprises the glycosylation site containing sequence C-(X)2-W-(X)12-16-N-Z-(S/T)-(X)3-5-C (SEQ ID NO:53), and wherein X is any amino acid and Z is any amino acid except proline.

### Claim 9 (depends on 8)

The DC modulatory protein of claim 8, wherein said protein comprises the glycosylation site containing sequence C-(X)2-W-(X)12-16-N-Z-(S/T)-(F/Y)-(X)2-4-C (SEQ ID NO:54), and wherein X is any amino acid and Z is any amino acid except proline.

### Claim 10 (depends on 8)

The DC modulatory protein of claim 8, wherein said protein comprises the glycosylation site containing sequence C-(X)2-W-(X)7-11-(I/L)-P-(X)3-N-Z-(S/T)-(X)3-5-C (SEQ ID NO:55), and wherein X is any amino acid and Z is any amino acid except proline.

### Claim 11 (depends on 8)

The DC modulatory protein of claim 8, wherein said protein comprises the glycosylation site sequence C-(X)2-W-(X)7-11-(I/L)-P-(X)3-N-Z-(S/T)-(F/Y)-(X)2-4-C (SEQ ID NO:56), and wherein X is any amino acid and Z is any amino acid except proline.

### Claim 12

The DC modulatory protein of any one of the preceding claims, wherein said protein is a lipocalin.

### Claim 13 (depends on 12)

The DC modulatory protein of claim 12, wherein said protein comprises the cysteine distribution pattern C-(X)82-91-C-(X)2-W-(X)19-23-C-(X)10-12-C (SEQ ID NO:71), and wherein X is any amino acid.

### Claim 14 (depends on 7, 8, 9, 10, 11, 12, 13)

The DC modulatory protein of any one of claims 7-13, wherein said protein comprises the cysteine distribution pattern and glycosylation site sequence C-(X)82-91-C-(X)2-W-(X)12-16-N-Z-(S/T)-(X)4-C-(X)10-12-C (SEQ ID NO:72), and wherein X is any amino acid and Z is any amino acid except proline.

### Claim 15

The DC modulatory protein of any one of the preceding claims, wherein said protein comprises the motif CXXW (SEQ ID NO:33), and wherein X is any amino acid.

### Claim 16 (depends on 15)

The DC modulatory protein of claim 15, wherein said protein comprises the motif CXLW (SEQ ID NO:34), and wherein X is any amino acid.

### Claim 17 (depends on 15, 16)

The DC modulatory protein of claim 15 or claim 16, wherein said protein comprises the motif CSLW (SEQ ID NO:35) or CELW (SEQ ID NO:36).

### Claim 18

The DC modulatory protein of any one of the preceding claims, wherein said protein is complexed to a lipid.

### Claim 19 (depends on 18)

The DC modulatory protein of claim 18, wherein the lipid is a steroid or a sterol.

### Claim 20 (depends on 18)

The DC modulatory protein of claim 18, wherein the lipid is cholesterol or a metabolite of cholesterol, such as vitamin D3 or dexamethasone.

### Claim 21

The DC modulatory protein of any one of the preceding claims, wherein said protein modulates human DC differentiation and maturation.

### Claim 22

The DC modulatory protein of any one of the preceding claims, wherein said protein inhibits DC differentiation and maturation.

### Claim 23

The DC modulatory protein of any one of the preceding claims, which is isolated from a haematophagous arthropod.

### Claim 24 (depends on 23)

The DC modulatory protein of claim 23, wherein protein is isolated from a tick.

### Claim 25 (depends on 24)

The DC modulary protein of claim 24, wherein the tick is selected from the group Ixodes, Bothriocrotoninae, Amblyomminae, Haemaphysalinae, Rhipicephaiinae (including Hyalomminae), Nuttalliellidae, Argasinae, Otobinae, Antricolinae, Nothhoaspinae and Ornithodorinae.

### Claim 26

The DC modulatory protein of any one of the preceding claims, wherein said protein inhibits T lymphocyte activation.

### Claim 27

The DC modulatory protein of any one of the preceding claims, wherein said protein modulates T lymphocyte polarisation.

### Claim 28

The DC modulatory protein of any one of the preceding claims, wherein said protein is an immunosuppressant.

### Claim 29

The DC modulatory protein of any one of the preceding claims which binds to a receptor present on the outer membrane of a DC.

### Claim 30 (depends on 29)

The DC modulatory protein of claim 29, which binds to a C-type lectin receptor.

### Claim 31

A nucleic acid molecule comprising a nucleic acid sequence encoding a DC modulatory protein according to any one of the preceding claims.

### Claim 32 (depends on 31)

The nucleic acid molecule of claim 31, comprising any one of SEQ ID NOS: 1, 3, or 5.

### Claim 33 (depends on 31, 32)

A nucleic acid molecule which hybridises under high stringency hybridisation conditions to a nucleic acid molecule according to claim 31 or claim 32.

### Claim 34 (depends on 31, 32, 33)

A vector comprising a nucleic acid molecule of any one of claims 31-33.

### Claim 35 (depends on 31, 32, 33, 34)

A host cell comprising the vector of claim 34 or a nucleic acid molecule according to any one of claims 31-33.

### Claim 36 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35)

A method of preparing a DC modulatory protein according to any one of claims 1-30 comprising culturing a host cell according to claim 35 under conditions whereby said protein is expressed, and recovering said protein thus produced.

### Claim 37 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30)

An antibody which binds to the DC modulatory protein, according to any one of claims 1-30.

### Claim 38 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 37)

A method of modulating a DC comprising contacting said DC with a DC modulatory protein of any one of claims 1-30, the nucleic acid of any one of claims 31-33, the vector of claim 34, the host cell of claim 35, or the antibody of claim 37.

### Claim 39 (depends on 38)

A modulated DC produced by the method of claim 38.

### Claim 40 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 37, 39)

A pharmaceutical composition comprising the DC modulatory protein of any one of claims 1-30, the nucleic acid of any one of claims 31-33, the vector of claim 34, the host cell of claim 35, the antibody of claim 37 or the DC of claim 39 and a pharmaceutically acceptable carrier.

### Claim 41 (depends on 40)

The pharmaceutical composition of claim 40 further comprising one or more additional therapeutic agents.

### Claim 42 (depends on 41)

The pharmaceutical composition of claim 41, wherein the one or more additional therapeutic agents comprises an anti-inflammatory agent, an immunomodulatory agent, an immunosuppressant, a cytokine, a cytokine mimetic or a cytokine binding protein.

### Claim 43 (depends on 40, 41, 42)

The pharmaceutical composition of any one of claims 40-42, wherein the one or more therapeutic agents comprises a disease-associated element.

### Claim 44 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 37, 39, 40, 41, 42, 43)

The DC modulatory protein of any one of claims 1-30, the nucleic acid of any one of claims 31-33, the vector of claim 34, the host cell of claim 35, the antibody of claim 37, the DC of claim 39 or the pharmaceutical composition of any one of claims 40-43 for use in therapy.

### Claim 45 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 37, 39, 40, 41, 42, 43)

The DC modulatory protein of any one of claims 1-30, the nucleic acid of any one of claims 31-33, the vector of claim 34, the host cell of claim 35, the antibody of claim 37 the DC of claim 39 or the pharmaceutical composition of any one of claims 40-43 for use in the treatment or prevention of autoimmune disorders, transplant reactions such as transplant rejection, acute and chronic inflammatory diseases, allergies or other immune-related sensitivities such as hypersensitivity.

### Claim 46 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 37, 39, 40, 41, 42, 43)

The DC modulatory protein of any one of claims 1-30, the nucleic acid of any one of claims 31-33, the vector of claim 34, the host cell of claim 35, the antibody of claim 37, the DC of claim 39 or the pharmaceutical composition of any one of claims 40-43 for use in the treatment or prevention of infectious disease including arthropod-borne diseases.

### Claim 47 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 37, 39, 40, 41, 42, 43)

The DC modulatory protein of any one of claims 1-30, the nucleic acid of any one of claims 31-33, the vector of claim 34, the host cell of claim 35, the antibody of claim 37, the DC of claim 39 or the pharmaceutical composition of any one of claims 40-43 for use in the treatment or prevention of cancer.

### Claim 48 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 37, 39, 40, 41, 42, 43)

A method of treating an animal suffering from autoimmune disorders, transplant reactions such as transplant rejection, acute and chronic inflammatory diseases, allergies or other immune-related sensitivities such as hypersensitivity comprising administering to said animal the DC modulatory protein of any one of claims 1-30, the nucleic acid of any one of claims 31-33, the vector of claim 34, the host cell of claim 35, the antibody of claim 37, the DC of claim 39 or the pharmaceutical composition of any one of claims 40-43 in a pharmaceutically effective amount.

### Claim 49 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 37, 39, 40, 41, 42, 43)

A method of treating an animal suffering an infectious disease including arthropod-borne diseases comprising administering to said animal the DC modulatory protein of any one of claims 1-30, the nucleic acid of any one of claims 31-33, the vector of claim 34, the host cell of claim 35, the antibody of claim 37, the DC of claim 39 or the pharmaceutical composition of any one of claims 40-43 in a pharmaceutically effective amount.

### Claim 50 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 37, 39, 40, 41, 42, 43)

A method of treating an animal suffering from cancer comprising administering to said animal the DC modulatory protein of any one of claims 1-30, the nucleic acid of any one of claims 31-33, the vector of claim 34, the host cell of claim 35, the antibody of claim 37, the DC of claim 39 or the pharmaceutical composition of any one of claims 40-43 in a pharmaceutically effective amount.

### Claim 51 (depends on 44, 45, 46, 47, 48, 49, 50)

The method of any one of claims 48-50 or the DC modulatory protein, nucleic acid, vector, host cell, antibody, DC or pharmaceutical composition of any of claims 44-47, wherein the DC modulatory protein, nucleic acid, vector, host cell, antibody, DC or pharmaceutical composition is administered in combination with a disease-associated element.

### Claim 52 (depends on 51)

The method of claim 51, or the DC modulatory protein, nucleic acid, vector, host cell, antibody, DC or pharmaceutical composition of claim 51, wherein the disease-associated element is selected from: components associated with infectious agents; allergens; non-self components associated with hypersensitivity reactions other than allergy; self components associated with autoimmune disease; transplantation antigens; blood group antigens; and tumour antigens.
